Cidara Therapeutics Inc
NASDAQ:CDTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cidara Therapeutics Inc
NASDAQ:CDTX
|
US |
|
A
|
Autozi Internet Technology (Global) Ltd
NASDAQ:AZI
|
CN |
|
S
|
South East PetroVietnam Fertilizer and Chemicals JSC
VN:PSE
|
VN |
|
V
|
Vsolar Group Bhd
KLSE:VSOLAR
|
MY |
|
Merit Interactive Co Ltd
SZSE:300766
|
CN |
|
A
|
Amneal Pharmaceuticals Inc
F:2DT
|
US |
|
URU Metals Ltd
LSE:URU
|
CA |
|
G
|
GuocoLand (Malaysia) Bhd
KLSE:GUOCO
|
MY |
Cidara Therapeutics Inc
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Phase III Acceleration: Cidara's lead candidate, CD388, advanced into Phase III six months ahead of schedule, with enrollment over 50% complete and on track to finish in December.
Expanded Patient Population: The FDA requested inclusion of healthy adults over 65 in the Phase III trial, doubling the eligible U.S. patient population from 50 million to over 100 million.
Strong Efficacy & Safety: Phase IIb data showed a single dose of CD388 provided 76.1% protective efficacy for the full flu season, with sustained drug levels and a clean safety profile.
Regulatory Momentum: CD388 received FDA breakthrough therapy designation in October, providing benefits like priority review and rolling data submissions.
Major BARDA Funding: Cidara secured up to $339 million in BARDA funding, including $58 million for manufacturing onshoring and additional support for clinical development.
Financial Strength: With $476 million in cash as of September 30, the Phase III program is fully funded, including possible expansion to the Southern Hemisphere.
